skip to content

Market News

PureTech notes Phase 2b study of mTORC1

09 May 2017 10:01

PureTech Health has confirmed the initiation of a Phase 2b study of its mechanistic target of rapamycin complex 1 (mTORC1) programme by subsidiary resTORbio.

The study would evaluate the effectiveness of RTB101 alone or in combination with RAD001 in reducing the incidence of respiratory tract infections (RTIs) in elderly patients at increased risk of morbidity and mortality related to RTIs.

Low doses of RTB101 alone or in combination with RAD001 have previously been shown to target mTORC1 selectively.

At 10:01am: (LON:PRTC) PureTech Health Plc share price was -0.38p at 116.5p

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.